Page last updated: 2024-11-13

7,8-dihydroxy-3-methylisochroman-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7,8-dihydroxy-3-methylisochroman-4-one: has antihypertensive activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25256788
CHEMBL ID492368
MeSH IDM000597499

Synonyms (6)

Synonym
CHEMBL492368
7,8-dihydroxy-3-methylisochroman-4-one
CS-0499235
DTXSID101237257
7,8-dihydroxy-3-methyl-1h-2-benzopyran-4(3h)-one
945619-75-0
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1891869Antihypertensive activity in spontaneous hypertensive rat model assessed as systolic blood pressure at 80 mg/kg, po measured after 8 hr by tail cuff method (Rvb = 186.1 +/- 4.6 mmHg)2022Bioorganic & medicinal chemistry, 06-15, Volume: 64Design, synthesis and biological evaluation of hydrogen sulfide-releasing isochroman-4-one derivatives as new antihypertensive agent candidates.
AID417971Acute antihypertensive activity in two-kidney one-clip renal hypertensive rat assessed as reduction in systolic arterial pressure at 100 mg/kg/day2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID417972Acute antihypertensive activity in two-kidney one-clip renal hypertensive rat assessed as reduction in diastolic arterial pressure at 100 mg/kg/day2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID1891866Antihypertensive activity in spontaneous hypertensive rat model assessed as systolic blood pressure at 80 mg/kg, po measured after 2 hr by tail cuff method (Rvb = 186.1 +/- 4.6 mmHg)2022Bioorganic & medicinal chemistry, 06-15, Volume: 64Design, synthesis and biological evaluation of hydrogen sulfide-releasing isochroman-4-one derivatives as new antihypertensive agent candidates.
AID1891867Antihypertensive activity in spontaneous hypertensive rat model assessed as systolic blood pressure at 80 mg/kg, po measured after 4 hr by tail cuff method (Rvb = 186.1 +/- 4.6 mmHg)2022Bioorganic & medicinal chemistry, 06-15, Volume: 64Design, synthesis and biological evaluation of hydrogen sulfide-releasing isochroman-4-one derivatives as new antihypertensive agent candidates.
AID417978Inhibition of pig lung ACE at 100 nmol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID717089Antihypertensive activity in spontaneously hypertensive rat assessed as reduction of diastolic arterial pressure at 40 mg/kg, po up to 24 hrs2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Novel nitric oxide-releasing isochroman-4-one derivatives: Synthesis and evaluation of antihypertensive activity.
AID417976Inhibition of pig lung ACE at 10 umol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID702934Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in systolic arterial pressure at 80 mg/kg, po measured up to 24 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4.
AID417977Inhibition of pig lung ACE at 1 umol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID702932Toxicity in spontaneously hypertensive rat assessed as change in basal heart rate at 50 mg/kg, po measured up to 24 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4.
AID417975Inhibition of pig lung ACE at 100 umol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID417979Inhibition of pig lung ACE at 10 nmol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID702936Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in diastolic arterial pressure at 80 mg/kg, po up to 24 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4.
AID417980Inhibition of pig lung ACE at 100 pmol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID1891868Antihypertensive activity in spontaneous hypertensive rat model assessed as systolic blood pressure at 80 mg/kg, po measured after 6 hr by tail cuff method (Rvb = 186.1 +/- 4.6 mmHg)2022Bioorganic & medicinal chemistry, 06-15, Volume: 64Design, synthesis and biological evaluation of hydrogen sulfide-releasing isochroman-4-one derivatives as new antihypertensive agent candidates.
AID702931Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in mean arterial pressure at 80 mg/kg, po up to 24 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4.
AID417981Inhibition of pig lung ACE at 10 pmol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID417982Inhibition of pig lung ACE at 1 pmol/L assessed as enzyme restrain rate2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4.
AID1891865Antihypertensive activity in spontaneous hypertensive rat model assessed as systolic blood pressure at 80 mg/kg, po measured after 1 hr by tail cuff method (Rvb = 186.1 +/- 4.6 mmHg)2022Bioorganic & medicinal chemistry, 06-15, Volume: 64Design, synthesis and biological evaluation of hydrogen sulfide-releasing isochroman-4-one derivatives as new antihypertensive agent candidates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]